PubMed · 11152177
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
D L Morris, V K Sabnis, G F Kroker, M S Morris. 2000. Immunotherapy.. https://doi.org/10.1016/s1081-1206(10)62584-7
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Low-dose vaccination has been proposed as a cost-saving strategy to implement mass vaccination of neonates with hepatitis B (HB) vaccine, world-wide, particularly in developing countries. The effectiveness of low vaccine doses, however, needs to be evaluated and verified in newborns from different ethnic backgrounds. In this study, a recombinant HB vaccine (Heberbiovac) was administered in three different doses, including the standard 10 microg together with 5 and 2.5 microg to three groups of healthy Iranian neonates. Each group, consisting of 230-260 subjects, received triple doses of vaccine given i.m. at 0, 1.5 and 9 month intervals. Serum samples were collected 2-4 weeks after completion of vaccination, and anti-HBs antibody was quantitated by a sandwich ELISA. Seroprotection (anti-HBs>10 IU/L) was detected in 92, 97.4 and 96.1% of 2.5, 5 and 10 microg vaccine dose recipients, with geometric mean titer (GMT) of 4502, 5824 and 6104 IU/L, respectively. No significant differences were observed in seroprotection rate and GMT between the 10 and 5 microg dose recipients. Both parameters, however, were significantly lower in neonates vaccinated with a 2.5 microg vaccine dose (P<0.05 and P<0.001, respectively). These findings indicate induction of a strong protective immune response in healthy Iranian neonates by a low dose (5 microg) of the recombinant HB vaccine.
Currently, about two-thirds of inmates in NSW correctional facilities have a history of injection drug use, and about half have serological evidence of exposure to hepatitis C virus. The introduction of an accelerated hepatitis B vaccination program (0-1-2 months) in 1998, using a 20 microg/dose vaccine was necessitated by the need to vaccinate eligible inmates in this high-risk environment characterised by rapid client mobility. Since 1999, both 10 and 20 microg doses of vaccine were introduced. We found that sero-response rates were not significantly influenced by HCV antibody status, but were significantly lower in cohorts of inmates vaccinated with the 10 microg dose of vaccine.
A safe food supply is a legitimate expectation of consumers, which the food industry must meet. Allergic reactions to food are recognised as a significant public health problem. Protecting allergic consumers against such reactions, while minimising the impact of food allergy on their quality of life, poses a challenge to the industry. Risk assessment is the process whereby the likelihood of an adverse event is related to exposure. Allergic reactions to foods can arise in one of three ways, which are not mutually exclusive. Firstly, a known allergen may be present in a food at a level above that at which the allergic individual reacts, secondly, an individual may react to a known or novel allergen because of sensitisation to another, cross-reactive, allergen and finally sensitisation may occur to a novel allergen, followed by reaction on subsequent exposure. A total absence of risk of reaction to an allergen implies no exposure, a situation which in most food manufacturing environments is unrealistic, and in any event would not help in the context of novel allergens. Possible approaches to risk assessment for food allergy in each of the contexts described above are examined, together with their limitations.